# BILL Holdings, Inc.: financial statements, quarterly

BILL · NYSE · CIK 1786352 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/bill.md) · [Financials](/companies/bill/financials.md) · [Filings](/companies/bill/filings.md) · [Insiders](/companies/bill/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bill/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [305](/filings/0001786352-24-000045.md) | [318](/filings/0001786352-25-000015.md) | [323](/filings/0001786352-25-000021.md) | [344 d](/filings/0001628280-26-058238.md) | [358](/filings/0001628280-25-050328.md) | [363](/filings/0001628280-26-005879.md) | [358](/filings/0001628280-26-032387.md) | [383 d](/filings/0001628280-26-058238.md) | [396](/filings/0001628280-25-050328.md) | [415](/filings/0001628280-26-005879.md) | [407](/filings/0001628280-26-032387.md) | [436 d](/filings/0001628280-26-058238.md) |
| Cost of revenue | $m | [56.0](/filings/0001786352-24-000045.md) | [58.4](/filings/0001786352-25-000015.md) | [55.0](/filings/0001786352-25-000021.md) | [65.2 d](/filings/0001628280-26-058238.md) | [64.7](/filings/0001628280-25-050328.md) | [66.6](/filings/0001628280-26-005879.md) | [67.2](/filings/0001628280-26-032387.md) | [73.6 d](/filings/0001628280-26-058238.md) | [77.0](/filings/0001628280-25-050328.md) | [83.6](/filings/0001628280-26-005879.md) | [74.7](/filings/0001628280-26-032387.md) | [80.0 d](/filings/0001628280-26-058238.md) |
| Gross profit | $m | [249](/filings/0001786352-24-000045.md) | [260](/filings/0001786352-25-000015.md) | [268](/filings/0001786352-25-000021.md) | [278 d](/filings/0001628280-26-058238.md) | [294](/filings/0001628280-25-050328.md) | [296](/filings/0001628280-26-005879.md) | [291](/filings/0001628280-26-032387.md) | [310 d](/filings/0001628280-26-058238.md) | [319](/filings/0001628280-25-050328.md) | [331](/filings/0001628280-26-005879.md) | [332](/filings/0001628280-26-032387.md) | [356 d](/filings/0001628280-26-058238.md) |
| Research and development | $m | [89.1](/filings/0001786352-24-000045.md) | [86.5](/filings/0001786352-25-000015.md) | [81.6](/filings/0001786352-25-000021.md) | [79.6 d](/filings/0001628280-26-058238.md) | [78.7](/filings/0001628280-25-050328.md) | [84.8](/filings/0001628280-26-005879.md) | [86.5](/filings/0001628280-26-032387.md) | [90.1 d](/filings/0001628280-26-058238.md) | [80.3](/filings/0001628280-25-050328.md) | [82.8](/filings/0001628280-26-005879.md) | [74.4](/filings/0001628280-26-032387.md) | [63.1 d](/filings/0001628280-26-058238.md) |
| Operating income | $m | [(56.6)](/filings/0001786352-24-000045.md) | [(67.7)](/filings/0001786352-25-000015.md) | [(27.6)](/filings/0001786352-25-000021.md) | [(22.2) d](/filings/0001628280-26-058238.md) | [(7.7)](/filings/0001628280-25-050328.md) | [(21.7)](/filings/0001628280-26-005879.md) | [(28.9)](/filings/0001628280-26-032387.md) | [(22.2) d](/filings/0001628280-26-058238.md) | [(20.7)](/filings/0001628280-25-050328.md) | [(18.1)](/filings/0001628280-26-005879.md) | [(0.4)](/filings/0001628280-26-032387.md) | [(34.3) d](/filings/0001628280-26-058238.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.5](/filings/0001786352-24-000045.md) | [1.7](/filings/0001786352-25-000015.md) | [0.4](/filings/0001786352-25-000021.md) | [0.0 d](/filings/0001628280-26-058238.md) | [1.3](/filings/0001628280-25-050328.md) | [0.0](/filings/0001628280-26-005879.md) | [1.3](/filings/0001628280-26-032387.md) | [4.0 d](/filings/0001628280-26-058238.md) | [0.1](/filings/0001628280-25-050328.md) | [0.5](/filings/0001628280-26-005879.md) | [2.0](/filings/0001628280-26-032387.md) | [(1.6) d](/filings/0001628280-26-058238.md) |
| Net income | $m | [(27.9)](/filings/0001786352-25-000021.md) | [(40.4)](/filings/0001786352-25-000021.md) | [31.8](/filings/0001786352-25-000021.md) | [7.6 d](/filings/0001628280-26-058238.md) | [8.9](/filings/0001628280-26-032387.md) | [33.5](/filings/0001628280-26-032387.md) | [(11.6)](/filings/0001628280-26-032387.md) | [(7.1) d](/filings/0001628280-26-058238.md) | [(3.0)](/filings/0001628280-26-032387.md) | [(2.6)](/filings/0001628280-26-032387.md) | [12.8](/filings/0001628280-26-032387.md) | [(18.5) d](/filings/0001628280-26-058238.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001786352-24-000045.md) | [(0.38)](/filings/0001786352-25-000015.md) | [0.00](/filings/0001786352-25-000021.md) | not reported | [0.08](/filings/0001628280-25-050328.md) | [(0.06)](/filings/0001628280-26-005879.md) | [(0.11)](/filings/0001628280-26-032387.md) | not reported | [(0.03)](/filings/0001628280-25-050328.md) | [(0.03)](/filings/0001628280-26-005879.md) | [0.12](/filings/0001628280-26-032387.md) | not reported |
| Basic EPS | $ per share | [(0.26)](/filings/0001786352-24-000045.md) | [(0.38)](/filings/0001786352-25-000015.md) | [0.30](/filings/0001786352-25-000021.md) | not reported | [0.08](/filings/0001628280-25-050328.md) | [0.33](/filings/0001628280-26-005879.md) | [(0.11)](/filings/0001628280-26-032387.md) | not reported | [(0.03)](/filings/0001628280-25-050328.md) | [(0.03)](/filings/0001628280-26-005879.md) | [0.13](/filings/0001628280-26-032387.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.5](/filings/0001786352-24-000045.md) | [1.6](/filings/0001786352-25-000015.md) | [1.0](/filings/0001786352-25-000021.md) | [1.0](/filings/0001628280-26-058238.md) | [0.9](/filings/0001628280-25-050328.md) | [1.6](/filings/0001628280-26-005879.md) | [1.0](/filings/0001628280-26-032387.md) | [1.0](/filings/0001628280-26-058238.md) | [1.1](/filings/0001628280-25-050328.md) | [1.1](/filings/0001628280-26-005879.md) | [1.0](/filings/0001628280-26-032387.md) | [1.0](/filings/0001628280-26-058238.md) |
| Current assets | $bn | [6.7](/filings/0001786352-23-000072.md) | [7.0](/filings/0001786352-24-000010.md) | [6.2](/filings/0001786352-24-000027.md) | [6.3](/filings/0001786352-25-000037.md) | [6.2](/filings/0001786352-24-000045.md) | [6.8](/filings/0001786352-25-000015.md) | [6.8](/filings/0001786352-25-000021.md) | [7.2](/filings/0001628280-26-058238.md) | [7.3](/filings/0001628280-25-050328.md) | [7.3](/filings/0001628280-26-005879.md) | [7.3](/filings/0001628280-26-032387.md) | [7.4](/filings/0001628280-26-058238.md) |
| Total assets | $bn | [9.6](/filings/0001786352-23-000072.md) | [9.9](/filings/0001786352-24-000010.md) | [9.1](/filings/0001786352-24-000027.md) | [9.2](/filings/0001786352-25-000037.md) | [9.0](/filings/0001786352-24-000045.md) | [9.7](/filings/0001786352-25-000015.md) | [9.6](/filings/0001786352-25-000021.md) | [10.1](/filings/0001628280-26-058238.md) | [10.2](/filings/0001628280-25-050328.md) | [10.1](/filings/0001628280-26-005879.md) | [10.1](/filings/0001628280-26-032387.md) | [10.2](/filings/0001628280-26-058238.md) |
| Current liabilities | $bn | [3.7](/filings/0001786352-23-000072.md) | [4.1](/filings/0001786352-24-000010.md) | [3.8](/filings/0001786352-24-000027.md) | [4.1](/filings/0001786352-25-000037.md) | [4.1](/filings/0001786352-24-000045.md) | [4.1](/filings/0001786352-25-000015.md) | [4.0](/filings/0001786352-25-000021.md) | [4.6](/filings/0001628280-26-058238.md) | [4.4](/filings/0001628280-25-050328.md) | [4.4](/filings/0001628280-26-005879.md) | [4.4](/filings/0001628280-26-032387.md) | [4.9](/filings/0001628280-26-058238.md) |
| Total liabilities | $bn | [5.5](/filings/0001786352-23-000072.md) | [5.9](/filings/0001786352-24-000010.md) | [5.1](/filings/0001786352-24-000027.md) | [5.0](/filings/0001786352-25-000037.md) | [5.0](/filings/0001786352-24-000045.md) | [5.9](/filings/0001786352-25-000015.md) | [5.8](/filings/0001786352-25-000021.md) | [6.1](/filings/0001628280-26-058238.md) | [6.3](/filings/0001628280-25-050328.md) | [6.3](/filings/0001628280-26-005879.md) | [6.3](/filings/0001628280-26-032387.md) | [6.7](/filings/0001628280-26-058238.md) |
| Long-term debt | $bn | [1.8](/filings/0001786352-23-000072.md) | [1.8](/filings/0001786352-24-000010.md) | [1.1](/filings/0001786352-24-000027.md) | [0.9](/filings/0001786352-25-000037.md) | [0.9](/filings/0001786352-24-000045.md) | [1.7](/filings/0001786352-25-000015.md) | [1.7](/filings/0001786352-25-000021.md) | [1.7](/filings/0001628280-26-058238.md) | [1.9](/filings/0001628280-25-050328.md) | [1.8](/filings/0001628280-26-005879.md) | [1.8](/filings/0001628280-26-032387.md) | [1.8](/filings/0001628280-26-058238.md) |
| Shareholders' equity | $bn | [4.1](/filings/0001786352-25-000021.md) | [4.0](/filings/0001786352-25-000021.md) | [4.1](/filings/0001786352-25-000021.md) | [4.1](/filings/0001628280-26-058238.md) | [4.0](/filings/0001628280-26-032387.md) | [3.8](/filings/0001628280-26-032387.md) | [3.9](/filings/0001628280-26-032387.md) | [3.9](/filings/0001628280-26-058238.md) | [3.9](/filings/0001628280-26-032387.md) | [3.8](/filings/0001628280-26-032387.md) | [3.8](/filings/0001628280-26-032387.md) | [3.5](/filings/0001628280-26-058238.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [53.7](/filings/0001786352-24-000045.md) | [79.7 d](/filings/0001786352-25-000015.md) | [66.8 d](/filings/0001786352-25-000021.md) | [78.6 d](/filings/0001628280-26-058238.md) | [88.6](/filings/0001628280-25-050328.md) | [78.7 d](/filings/0001628280-26-005879.md) | [99.5 d](/filings/0001628280-26-032387.md) | [83.8 d](/filings/0001628280-26-058238.md) | [96.9](/filings/0001628280-25-050328.md) | [105 d](/filings/0001628280-26-005879.md) | [103 d](/filings/0001628280-26-032387.md) | [111 d](/filings/0001628280-26-058238.md) |
| Capital expenditure | $m | [0.4](/filings/0001786352-23-000072.md) | [0.4 d](/filings/0001786352-24-000010.md) | [0.0 d](/filings/0001786352-25-000021.md) | [0.2 d](/filings/0001628280-26-058238.md) | [0.0](/filings/0001628280-25-050328.md) | [0.4 d](/filings/0001628280-26-005879.md) | [1.1 d](/filings/0001628280-26-032387.md) | [2.8 d](/filings/0001628280-26-058238.md) | [1.3](/filings/0001628280-25-050328.md) | [1.5 d](/filings/0001628280-26-005879.md) | [0.2 d](/filings/0001628280-26-032387.md) | [0.4 d](/filings/0001628280-26-058238.md) |
| Share repurchases | $m | [12.1](/filings/0001786352-24-000045.md) | [200 d](/filings/0001786352-25-000015.md) | [0.0 d](/filings/0001786352-25-000021.md) | [0.0 d](/filings/0001628280-26-058238.md) | [200](/filings/0001628280-25-050328.md) | [200 d](/filings/0001628280-26-005879.md) | [0.0 d](/filings/0001628280-26-032387.md) | [30.0 d](/filings/0001628280-26-058238.md) | [83.1](/filings/0001628280-25-050328.md) | [133 d](/filings/0001628280-26-005879.md) | [56.9 d](/filings/0001628280-26-032387.md) | [288 d](/filings/0001628280-26-058238.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [105](/filings/0001786352-23-000072.md) | [106](/filings/0001786352-24-000010.md) | [107](/filings/0001786352-24-000027.md) | [107](/filings/0001786352-24-000045.md) | [106](/filings/0001786352-25-000015.md) | [111](/filings/0001786352-25-000021.md) | [107](/filings/0001628280-25-050328.md) | [104](/filings/0001628280-26-005879.md) | [102](/filings/0001628280-26-032387.md) | [102](/filings/0001628280-25-050328.md) | [101](/filings/0001628280-26-005879.md) | [113](/filings/0001628280-26-032387.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 85,276,782 at 2026-08-13, from the cover of the [10-K filed 2026-08-20](/filings/0001628280-26-058238.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.